Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 5/20 | 0.32 |
| ▸ | HCRTR2 | O43614 | 5/20 | 0.32 |
| ▸ | NPC1 | O15118 | 3/20 | 0.32 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.32 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.31 |
| ▸ | RET | P07949 | 4/20 | 0.31 |
| ▸ | PLAT | P00750 | 1/20 | 0.31 |
| ▸ | ACP1 | P24666 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | STAT3 | P40763 | 1/20 | 0.30 |
| ▸ | STAT1 | P42224 | 1/20 | 0.30 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.30 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3927571 | 0.85 | HCRTR1 (0.35) | HCRTR1HCRTR2ALOX5APRET | |
| SCHEMBL3922291 | 0.84 | SMYD3 (0.35) | HCRTR1HCRTR2ALOX5APRET | |
| SCHEMBL11843303 | 0.83 | STAT3 (0.43) | NPC1RAB9AALDH1A1RETPLAT | |
| SCHEMBL3919791 | 0.82 | BACE1 (0.32) | HCRTR1HCRTR2RET | |
| SCHEMBL3858720 | 0.82 | HCRTR1 (0.47) | HCRTR1HCRTR2ALOX5APACP1 | |
| SCHEMBL3851051 | 0.80 | NPC1 (0.31) | NPC1RAB9AALDH1A1 | |
| SCHEMBL3853970 | 0.79 | NPC1 (0.40) | NPC1RAB9AALDH1A1MAPTPKM | |
| SCHEMBL3919389 | 0.77 | CHRNB2 (0.50) | ACP1CHRNB2CHRNA4 | |
| SCHEMBL3922338 | 0.77 | CHRNB2 (0.50) | ACP1CHRNB2CHRNA4 | |
| SCHEMBL4917420 | 0.75 | HCRTR1 (0.35) | HCRTR1HCRTR2NPC1RAB9ARET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1663204-A4 | C-KIT MODULATORS AND METHODS OF USE | EXELIXIS INC (US) | 2008-08-13 | — | — | EP | claimed |
| JP-2007504160-A | — | — | 2007-03-01 | — | — | JP | claimed |
| EP-1663204-A2 | C-KIT MODULATORS AND METHODS OF USE | Exelixis, Inc. (US) | 2006-06-07 | — | — | EP | claimed |
| WO-2005020921-A2 | C-KIT MODULATORS AND METHODS OF USE | EXELIXIS, INC. (US) | 2005-03-10 | — | — | WO | claimed |
| EP-1869032-B8 | PYRIMIDINE DERIVATIVES FOR USE AS ANTICANCER AGENTS | ASTRAZENECA AB (SE) | 2009-03-25 | — | — | EP | disclosed |
| EP-1869032-B1 | PYRIMIDINE DERIVATIVES FOR USE AS ANTICANCER AGENTS | ASTRAZENECA AB (SE) | 2008-08-13 | — | — | EP | disclosed |
| US-20080167297-A1 | Pyrimidine Derivatives for Use as Anticancer Agents | ASTRAZENECA AB (SE) | 2008-07-10 | — | — | US | disclosed |
| EP-1869032-A1 | PYRIMIDINE DERIVATIVES FOR USE AS ANTICANCER AGENTS | AstraZeneca AB (SE) | 2007-12-26 | — | — | EP | disclosed |
| WO-2006106307-A1 | PYRIMIDINE DERIVATIVES FOR USE AS ANTICANCER AGENTS | ASTRAZENECA AB (SE) | 2006-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167297-A1 | Pyrimidine Derivatives for Use as Anticancer Agents | IGF1R, TYMP, IGFBP1 | HCRTR1 4170/4885HCRTR2 4357/4885NPC1 2756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.